NatalieSCallanderMD

Oncology • Madison, WI

Hematologic Oncology

Associate Professor, Medicine, University of Wisconsin Medical School

Join to view full profile

Dr. Callander is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Callander's full profile

Already have an account?

Office
600 Highland Ave
Madison, WI 53792
Phone+1 608-265-1700

Fax+1 608-266-6020
Is this information wrong?

Education & Training

University of California (San Diego) Medical CenterFellowship, Hematology and Medical Oncology, 1988 - 1991
NYU Grossman School of MedicineResidency, Internal Medicine, 1985 - 1988
Tufts University School of MedicineClass of 1985

Certifications & Licensure

CA State Medical License 1988 - Present
WI State Medical License 2004 - 2025
TX State Medical License 1995 - 2024
GA State Medical License 1989 - 1989
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011

Clinical Trials

Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple Myeloma Start of enrollment: 2006 Nov 01
Completed
Phase 2
Ph 2 Bortezomib, Dexamethasone, + Doxorubicin With ALCAR for Previously Treated Multiple Myeloma Start of enrollment: 2004 Feb 01
Completed
Phase 2
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma Start of enrollment: 2008 Feb 29
Active, not recruiting
Phase 3
Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma Start of enrollment: 2008 Apr 01
Active, not recruiting
Phase 3
Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant Start of enrollment: 2010 Sep 01
Terminated
Phase 2
Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma Start of enrollment: 2012 Dec 19
Completed
Phase 1
Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma Start of enrollment: 2014 Jul 23
Completed
Phase 1
MM CAR-T to Upgrade Response BMTCTN1902 Start of enrollment: 2022 Jan 05
Active, not recruiting
Phase 2
Roles: Contact
Selinexor and Backbone Treatments of Multiple Myeloma Patients Start of enrollment: 2015 Oct 01
Active, not recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Contact
COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide Start of enrollment: 2023 Jan 18
Recruiting
Phase 1, Phase 2
Roles: Contact
A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma Start of enrollment: 2017 Oct 04
Active, not recruiting
Phase 1, Phase 2
Roles: Principal Investigator
A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2023 Jan 26
Active, not recruiting
Phase 1, Phase 2
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

1 citations
Update on the current and future use of CAR-T to treat multiple myeloma.
Zhubin Gahvari, Matthew Brunner, Timothy Schmidt, Natalie S Callander> ;European Journal of Haematology. 2024 Apr 1
Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens:...
Michel Delforge, Krina Patel, Laurie Eliason, Devender Dhanda, Ling Shi, Shien Guo, Thomas S Marshall, Bertrand Arnulf, Michele Cavo, Ajay Nooka, Salomon Manier, Natal...> ;The Lancet. Haematology. 2024 Mar 1
Impact of Visceral Obesity on Clinical Outcome and Quality of Life for Patients with Multiple Myeloma: A Secondary Data Analysis of STaMINA (BMT CTN 0702) Trial.
Fu, P., Li, G., Malek, E., Kort, J., Metheny, L., Hari, P., Efebera, Y., Callander, N., Qazilbash, M., Giralt, S., Krishnan, A., Stadtmauer, E., Lazarus, H.> ;Transplantation and Cellular Therapy. 2024 Jan 19
HAPLN1 matrikine: a bone marrow homing factor linked to poor outcomes in patients with MM.
Hae Yeun Chang, Mailee Huynh, Avtar Roopra, Natalie S Callander, Shigeki Miyamoto> ;Blood Advances. 2023 Nov 28
1 citations
PD1TIGIT2B4KLRG1Cells Might Underlie T Cell Dysfunction in Patients Treated with BCMA-Directed Chimeric Antigen Receptor T Cell Therapy.
Ameet K Mishra, Timothy M Schmidt, Ella B Martell, Alex S Chen, Reyna E Dogru, Peiman Hematti, Natalie S Callander> ;Transplantation and Cellular Therapy. 2024 Feb 1
4 citations
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial.
Costa, L., Chhabra, S., Medvedova, E., Dholaria, B., Schmidt, T., Godby, K., Silbermann, R., Dhakal, B., Bal, S., Giri, S., D'Souza, A., Hall, A., Hardwick, P., Omel, ...> ;The Lancet. Haematology. 2023 Nov 1
2 citations
Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial.
Ajay K Nooka, Adam D Cohen, Hans C Lee, Ashraf Badros, Attaya Suvannasankha, Natalie Callander, Al-Ola Abdallah, Suzanne Trudel, Ajai Chari, Edward N Libby, Maria Chau...> ;Cancer. 2023 Dec 1
TCR-α/β and CD19 depleted stem cell grafts from haploidentical donors for allogeneic transplantation in patients with relapsed lymphoma: a single-center experience.
Vaishalee P Kenkre, Kristin Bradley, Arissa Milton, Joseph K Burkholder, Kreg Grindle, Jan McMannes, KyungMann Kim, Natalie Callander, Mark Juckett, Walter Longo, Peim...> ;Leukemia & Lymphoma. 2023 Aug 10
2 citations
Humoral immune reconstitution following therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd), autologous hematopoietic cell transplantatio...
Rebecca W Silbermann, Timothy Martin Schmidt, Susan Bal, Binod Dhakal, Bhagirathbhai Dholaria, Eden Biltibo, Saurabh Chhabra, Smith Giri, Kelly N Godby, Sonia Gowda, E...> ;Ejhaem. 2023 Aug 1
13 citations
Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma.
Meera Mohan, Rajshekhar Chakraborty, Susan Bal, Anoma Nellore, Muhamed Baljevic, Anita D'Souza, Peter G Pappas, Jesus G Berdeja, Natalie Callander, Luciano J Costa> ;British Journal of Haematology. 2023 Dec 1
Molecular characterization stratifies VQ myeloma cells into two clusters with distinct risk signatures and drug responses.
Evan Flietner, Mei Yu, Govinda Poudel, Anthony J Veltri, Yun Zhou, Adhithi Rajagopalan, Yubin Feng, Terra Lasho, Zhi Wen, Yuqian Sun, Mrinal M Patnaik, Natalie S Calla...> ;Oncogene. 2023 May 1
5 citations
Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.
Shaji K Kumar, Natalie S Callander, Kehinde Adekola, Larry D Anderson Jr, Muhamed Baljevic, Erica Campagnaro, Jorge J Castillo, Caitlin Costello, Christopher D'Angelo,...> ;Journal of the National Comprehensive Cancer Network. 2023 Jan 1
13 citations
Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER ...
Saurabh Chhabra, Natalie Callander, Nicole L Watts, Luciano J Costa, Bicky Thapa, Jonathan L Kaufman, Jacob Laubach, Douglas W Sborov, Brandi Reeves, Cesar Rodriguez, ...> ;Transplantation and Cellular Therapy. 2023 Mar 1
10 citations
Selinexor-based regimens in patients with multiple myeloma after prior anti-B-cell maturation antigen treatment.
Muhamed Baljevic, Cristina Gasparetto, Gary J Schiller, Sascha A Tuchman, Natalie S Callander, Suzanne Lentzsch, Jorge Monge, Rami Kotb, Nizar J Bahlis, Darrell White,...> ;Ejhaem. 2022 Nov 1
7 citations
Perturbation of the gut microbiome and association with outcomes following autologous stem cell transplantation in patients with multiple myeloma.
Christopher D'Angelo, Sailendharan Sudakaran, Fotis Asimakopoulos, Peiman Hematti, Dalia El-Gamal, Nasia Safdar, Natalie Callander> ;Leukemia & Lymphoma. 2023 Jan 1
3 citations
Clinical implications of measurable residual disease assessment in multiple myeloma in the era of quadruplet therapy.
Susan Bal, Timothy M Schmidt, Luciano J Costa, Natalie S Callander> ;Leukemia & Lymphoma. 2022 Dec 1
4 citations
Iopofosine I-131 treatment in late-line patients with relapsed/refractory multiple myeloma post anti-BCMA immunotherapy.
Jarrod Longcor, Natalie Callander, Kate Oliver, Asher Chanan-Khan, Sikander Ailawadhi> ;Blood Cancer Journal. 2022 Sep 6
98 citations
Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma.
Costa, L., Chhabra, S., Medvedova, E., Dholaria, B., Schmidt, T., Godby, K., Silbermann, R., Dhakal, B., Bal, S., Giri, S., D'Souza, A., Hall, A., Hardwick, P., Omel, ...> ;Journal of Clinical Oncology. 2022 Sep 1
1 citations
A biobehavioral intervention to enhance recovery following hematopoietic cell transplantation: Protocol for a feasibility and acceptability randomized control trial.
Andrew Kirvin-Quamme, Meredith E Rumble, Lisa Cadmus-Bertram, Mark B Juckett, Paul J Rathouz, Gwynneth Schell, Natalie S Callander, Peiman Hematti, Erin S Costanzo> ;Contemporary Clinical Trials Communications. 2022 Aug 1
5 citations
Gender disparities in the National Institutes of Health funding for hematologic malignancies and cellular therapies.
Raheel Sufian Siddiqui, Sibgha Gull Chaudhary, Moazzam Shahzad, Iqra Anwar, Ali Hussain, Nausheen Ahmed, Sunil Hari Abhyankar, Leyla Shune, Peiman Hematti, Heather Mal...> ;Leukemia & Lymphoma. 2022 Jul 1
16 citations
Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee.
Shaji Kumar, Lawrence Baizer, Natalie S Callander, Sergio A Giralt, Jens Hillengass, Boris Freidlin, Antje Hoering, Paul G Richardson, Elena I Schwartz, Anthony Reiman...> ;Blood Cancer Journal. 2022 Jun 29
4 citations
Ponatinib sensitizes myeloma cells to MEK inhibition in the high-risk VQ model.
Evan Flietner, Zhi Wen, Adhithi Rajagopalan, Oisun Jung, Lyndsay Watkins, Joshua Wiesner, Xiaona You, Yun Zhou, Yuqian Sun, Brock Kingstad-Bakke, Natalie S Callander, ...> ;Scientific Reports. 2022 Jun 23
Timelapse viability assay to detect division and death of primary multiple myeloma cells in response to drug treatments with single cell resolution.
Christina Mark, Natalie S Callander, Kenny Chng, Shigeki Miyamoto, Jay Warrick> ;Integrative Biology. 2022 Jun 8
8 citations
ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma.
Binod Dhakal, Nina Shah, Ankit Kansagra, Ambuj Kumar, Sagar Lonial, Alfred Garfall, Andrew Cowan, Bishesh Sharma Poudyal, Caitlin Costello, Francesca Gay, Gordon Cook,...> ;Transplantation and Cellular Therapy. 2022 Jun 1
4 citations
A Hyaluronan and Proteoglycan Link Protein 1 Matrikine: Role of Matrix Metalloproteinase 2 in Multiple Myeloma NF-κB Activation and Drug Resistance.
Christina Mark, Jay Warrick, Natalie S Callander, Peiman Hematti, Shigeki Miyamoto> ;Molecular Cancer Research. 2022 Sep 2
Join now to see all

Abstracts/Posters

Novel Prognostic Scoring System for Autologous Hematopoietic Cell Transplantation (AHCT) in Multiple Myeloma (MM)
Natalie Scott Callander, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Allogeneic Hematopoietic Stem Cell Transplantation for Therapy-Related Myelodysplastic Syndromes and Acute Myeloid Leukemia
Natalie Scott Callander, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Phase 1b/2 Study of Selinexor, Carfilzomib, and Dexamethasone (SKd) in Relapsed/ Refractory Multiple Myeloma (RRMM)
Natalie Scott Callander, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...
Natalie Scott Callander, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Di...
Natalie Scott Callander, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Newly Diagnosed Multiple Myeloma
Natalie Scott Callander, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Versican Proteolytic Fragments (Matrikines) Regulate the Intratumoral Dendritic Cell Milieu In Vivo: Implications for in Situ Tumor Vaccination
Natalie Scott Callander, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Versican (VCAN) Proteolysis Predicts Survival in Multiple Myeloma (MM) after High Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT/AHCT)
Natalie Scott Callander, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...
Natalie Scott Callander, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Impact of Antibiotics on Gut Microbiota Diversity and the Results of a Prospective Dietary Assessment in Patients with Multiple Myeloma Undergoing Autologous Hematopoi...
Natalie Scott Callander, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

A Phase II Study of Decitabine Followed By Allogeneic Hematopoietic Stem Cell Transplantation in High-Risk Patients with Myeloid Malignancies
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Subsequent Treatment Outcomes of Multiple Myeloma Refractory to CD38-Monoclonal Antibody Therapy
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

COVID mRNA Vaccine Equally Safe for People with CancerFebruary 7th, 2022
COVID-19 Vaccines Are Safe for People with Cancer, Researchers SayFebruary 7th, 2022
Multiple Myeloma: Choosing Your PathDecember 18th, 2020
Join now to see all